Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Always Active
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.

年 신생아 22만명 앗아가는 내성균 대응 라이트재단·GARDP·제일약품 임상 착수 항생제 원료 원천기술 보유한 제일약품 세계 공중보건 프로젝트 핵심 공급처로

22 November 2023

hankookilbo logo

 

22 November 2023 

“지난해 패혈증 치료를 위해 맞은 항생제에 내성이 생겨 사망한 신생아가 세계적으로 22만 명에 달합니다. 내성 문제를 해결할 새 치료법을 적정 가격으로 개발하려고 뜻을 모았습니다.”

국제보건기술연구기금(라이트재단)과 제일약품, 글로벌 항생제 연구개발 비영리 국제단체(GARDP)가 21일 서울 여의도 IFC에서 만나 새로운 신생아 패혈증 치료제 개발의 첫발을 뗐다. 이 프로젝트를 위해 라이트재단은 GARDP와 제일약품에 각각 30억 원, 10억 원씩 총 40억 원을 지원하기로 지난 6일 계약을 맺었다. 이후 각사 책임자가 처음 공식적으로 만난 이날 이훈상 라이트재단 전략기획이사(CSO)는 “공공보건 증진이라는 목적에 한국 기업의 역할이 뚜렷하게 맞아떨어진 사례”라고 강조했다.

 

Read the article